Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results
2015 | 28 | 3 | 170-175

Article title

The influence of montelukast on the autonomic nervous system activity in rats with cyclophosphamide-induced hemorrhagic cystitis


Title variants

Languages of publication



The complex pathogenesis of cyclophosphamide-induced hemorrhagic cystitis involves arachidonic acid-derived inflammatory mediators, among them leukotrienes. Montelukast, a leukotriene receptor antagonist, is reported to exert an alleviatory effect in the course of cystitis associated with overactive bladder symptoms. The aim of this study was to verify whether the effect of montelukast is also associated with its influence on autonomic activity. The experiment included 20 rats with cyclophosphamide-induced hemorrhagic cystitis (75 mg/kg, four doses every second day), among them, 10 treated with oral montelukast (10 mg/kg for 8 days) and 10 controls. Time and frequency domain analyses of heart rate variability (HRV) were conducted in all the rats as an indirect measure of their autonomic activity. The montelukast-treated animals showed an increase in root mean square of successive differences (rMSSD), as well as an increase in HRV spectrum total power (TP) and power of very low (VLF) spectral component. This suggests that due to its anti-inflammatory and its anti-leukotriene effect, montelukast improves overall autonomic activity, with no preferential influence on either the sympathetic or parasympathetic part. Furthermore, the increase in VLF corresponds to attenuation of inflammatory response. In conclusion, this study showed that aside from its antagonistic effect on leukotriene receptors, montelukast can also modulate autonomic activity.









Physical description


1 - 9 - 2015
21 - 8 - 2015
26 - 11 - 2015
6 - 7 - 2015


  • Department of Pathophysiology, Jagiellonian University Collegium Medicum, Czysta 18, 31-121 Krakow, Poland
  • Department of Pathophysiology, Jagiellonian University Collegium Medicum, Czysta 18, 31-121 Krakow, Poland
  • Department of Pathophysiology, Jagiellonian University Collegium Medicum, Czysta 18, 31-121 Krakow, Poland
  • Department of Pathophysiology, Jagiellonian University Collegium Medicum, Czysta 18, 31-121 Krakow, Poland


  • 1. Altayli E. et al.: Prevention and treatment of cyclophosphamide and ifosfamide-induced hemorrhagic cystitis. J. Mol. Pathophysiol., 1, 53, 2012.
  • 2. Benarroch E.E.: Autonomic-mediated immunomodulation and potential clinical relevance. Neurology, 73, 236, 2009.[WoS]
  • 3. Bouchelouche K. et al.: Increased urinary leukotriene E4 and eosinophil protein X excretion in patients with interstitial cystitis. J. Urol., 166, 2121, 2001.
  • 4. Bouchelouche K. et al.: The action of cysteinyl-leukotrienes on intracelluar calcium mobilization in human detrusor myocytes. BJU Int., 87, 690, 2001.
  • 5. Bouchelouche K. et al.: The cysteinyl leukotriene D4 receptor antagonist montelukast fort the treatment of interstitial cystitis. J. Urol., 166, 1734, 2001.
  • 6. Chuang Y.C. et al.: Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and supresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats. Eur. Urol., 56, 159, 2009.
  • 7. Dobrek Ł., Baranowska A., Thor P.J.: The inf luence of oxazaphosphorines alkylating agents on autonomic nervous system activity in rat experimental cystitis model. Acta Pol. Pharm., 70, 1097, 2013.
  • 8. Dobrek Ł., Thor P.: Heart rate variability in overactive bladder experimental model. Arch. Med. Sci., 9, 930, 2013.[WoS][Crossref]
  • 9. Dobrek Ł., Thor P.J.: Bladder urotoxicity pathophysiology induced by the oxazaphosphorine alkylating agents and ist chemoprevention. Postepy Hig. Med. Dosw. (online), 66, 592, 2012.
  • 10. Girard B.M. et al.: Increased expression of interleukin-6 family members and receptors in urinary bladder with cyclophosphamideinduced bladder inflammation in female rats. Front. Neurosci., 5, article 20, 2011.[Crossref]
  • 11. Goncalves H. et al.: Analysis of heart rate variability in a rat model of induced pulmonary hypertension. Med. Eng. Phys., 32, 746, 2010.[WoS]
  • 12. Grover S. et al.: Role of inflammation in bladder function and interstitial cystitis. Ther. Adv. Urol., 3, 19, 2011.[Crossref]
  • 13. Haeggstrom J.Z., Funk C.D.: Lipooxygenase and leukotriene pathways: biochemistry, biology and roles in disease. Chem. Rev., 111, 5866, 2011.
  • 14. Huston J.M., Tracey K.J.: The pulse of inflammation: heart rate variability, the cholinergic anti-inf lammatory pathway and implications for therapy. J. Intern. Med., 269, 45, 2011.
  • 15. Karim N, Hasan JA, Ali SS. Heart rate variability - a review. J. Basic Appl. Sci., 7, 71, 2011.
  • 16. Lampert R. et al. : Decreased heart rate variability is associated with higher levels of inflammation in middle-aged men. Am. Heart J., 156, 759e1, 2008.[WoS]
  • 17. Lanza,G.A. et al.: Relation of heart rate variability to serum levels of C reactive protein in patients with unstable angina pectoris. Am. J. Cardiol., 97,1702, 2006.
  • 18. Lee G., Romih R., Zupancic D.: Cystitis: from urothelial cell biology to clinical application. Biomed. Res. Int., article ID 473536, 2014.
  • 19. Mohamadin A.M. et al.: Montelukast, a leukotriene receptor antagonist abrogates lipopolysaccharide-induced toxicity and oxidative stress in rat liver. Pathophysiology, 18, 235, 2011.[Crossref]
  • 20. Mukherjee N. et al.: Pre-treatment with amifostine protects against cyclophosphamide-induced disruption of taste in mice. PLoS ONE, 8, e61607, 2013.
  • 21. Nicolini A. et al.: Malnutrition, anorexia and cachexia in cancer patients: a mini review on pathogenesis and treatment. Biomed. Pharmacother., 67, 807, 2013.[WoS]
  • 22. No Authors listed. Heart rate variability. Standards of measurement, physiological interpretation and clinical use. Task Force of The European Society of Cardiology and The North American Society of Pacing and Electrophysiology. Eur. Heart J., 17, 354, 1996.
  • 23. Papaioannou V., Pneumatikos I., Maglaveras N.: Association of heart rate variability and inflammatory response in patients with cardiovascular diseases: current strengths and limitations. Front. Physiol., 4, 174, 2013.[WoS][Crossref]
  • 24. Rahnama’i M.S., van Koevringe G.A., van Kerrebroeck P.E.: Overactive bladder symptom and the potential role of prostaglandins and phosphodiesterases: an introduction. Nephro. Urol. Mon., 5, 933, 2013.[Crossref]
  • 25. Sztajzel J.: Heart rate variability: a noninvasive electrocardiographic method to measure the autonomic nervous system. Swiss. Med. Wkly. 134, 514, 2004.
  • 26. Tintinger G.R. et al.: Montelukast: more than a cysteinyl leukotriene receptor antagonist? ScientificWorldJournal, 10, 2403, 2010.[Crossref]
  • 27. Traut J.L. et al.: Montelukast for symptom control of interstitial cystitis. Ann. Pharmacother., 45, e49, 2011.
  • 28. Zeng J. et al.: Cause of residual urine in bladder outlet obstruction: an experimental study in the rat. J. Urol., 188, 1027, 2012. [WoS]

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.